NCT07653581Not yet recruitingPhase 3
rhTPO + CsA vs CsA in the Treatment of LR-MDS With Thrombocytopenia
rhTPO + CsA Versus CsA Alone in the Treatment of Lower-risk MDS With Thrombocytopenia: a Single-center Randomized Controlled Trial
Source: ClinicalTrials.gov · Last updated 17 Jun 2026
Brief summary (registry, in English)
This study aims to compare the efficacy and safety of recombinant human thrombopoietin (rhTPO) + cyclosporine (CsA) and CsA monotherapy in the treatment of lower-risk myelodysplastic neoplasms with thrombocytopenia.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- First submitted
- 7 Jun 2026
- Start date
- Jun 2026
- Primary completion date
- Dec 2028
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Myelodysplastic syndromes
- NCT number
- NCT07653581
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 78
- From Jun 2026 to the primary completion date, Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any concurrent malignant tumors within the past 5 years, or basal cell carcinoma of the skin at the local site;
- Previously received cyclosporine (CsA) or ATG within 6 months;
- Previously used IL-11, rhTPO or TPO-RA;
Other illness
- History of leukemia or stem cell transplantation, treatment-related MDS or malignant tumors;
- Infections or bleeding that cannot be controlled by standard treatment;
- History of thromboembolic events, heart attack or stroke and current use of anticoagulants;
Other
- With splenomegaly or myelofibrosis;
- Pregnant or lactating women;
- Participated in other clinical trials within 3 months.
Who the study is looking for
- Age ≥ 18 years old;
- Confirmed diagnosis of lower-risk MDS;
- Platelet ≤ 30×109/L, or \< 50×109/L and accompanied by bleeding events;
- Baseline liver and kidney functions \<2 ULN;
- Signed the informed consent form;
- ECOG 0-2;
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.